Skip to main content

Table 1 Baseline characteristics of 39 patients with high-risk non-Hodgkin’s lymphoma

From: Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

Characteristic

R-CHOP [cases (%)]

CHOP [cases (%)]

P value

Total

14

25

 

Sex

  

0.673

 Male

8 (57.1)

16 (64.0)

 

 Female

6 (42.9)

9 (36.0)

 

Tumor origin

  

<0.001

 B-cell

14 (100.0)

8 (32.0)

 

 T-cell

0

15 (60.0)

 

 NA

0

2 (8.0)

 

Ann arbor stage

  

0.119

 I/II

1 (7.1)

8 (32.0)

 

 III/IV

13 (92.9)

17 (68.0)

 

ECOG score

  

0.289

 <2

13 (92.9)

23 (92.0)

 

 ≥2

1 (7.1)

2 (8.0)

 

LDH level (IU/L)

  

0.328

 >225

9 (64.3)

12 (48.0)

 

 ≤225

5 (35.7)

13 (52.0)

 

B symptoms

  

0.089

 No

5 (35.7)

16 (64.0)

 

 Yes

9 (64.3)

9 (36.0)

 

Bulky disease

  

0.431

 No

6 (42.9)

14 (56.0)

 

 Yes

8 (57.1)

11 (44.0)

 

Extranodal invasion

  

0.652

 No

3 (21.4)

7 (28.0)

 

 Yes

11 (78.6)

18 (72.0)

 

aaIPI

  

0.096

 0–1

4 (28.6)

15 (60.0)

 

 2–3

10 (71.4)

10 (20.0)

 

Disease status before mobilization

 

0.201

 CR

8 (57.1)

9 (36.0)

 

 PR

6 (42.9)

16 (64.0)

 

Previous radiation therapy

0

2 (8.0)

0.528

  1. R-CHOP rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimen; CHOP, CHOP or CHOP-like regimen without rituximab; ECOG Eastern Cooperative Oncology Group; LDH lactate dehydrogenase; aaIPI age-adjusted International Prognostic Index; CR complete response; PR partial response; NA not available